PLSE

Pulse Biosciences Inc

Add to Watchlist

Advanced Chart

14.880

+0.17(1.156%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

14.9821

Open

14.550

VWAP

14.73

Vol

126.65K

Mkt Cap

1.00B

Low

14.490

Amount

1.87M

EV/EBITDA(TTM)

Total Shares

55.23M

870.32M

EV/OCF(TTM)

P/S(TTM)

Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.

1 Analyst Rating

47.85% Upside

Wall Street analysts forecast PLSE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLSE is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

47.85% Upside

Current: 14.880

Low

22.00

Averages

22.00

High

22.00

47.85% Upside

Current: 14.880

Low

22.00

Averages

22.00

High

22.00

Oppenheimer

Suraj Kalia

Outperform

initiated

$22

2025-07-07

Reason

Oppenheimer

Suraj Kalia

Price Target

$22

2025-07-07

initiated

Outperform

Reason

Oppenheimer analyst Suraj Kalia initiated coverage of Pulse Biosciences with an Outperform rating and $22 price target. The company has developed nanosecond pulsed field ablation technology and preliminary evidence suggests a better safety and efficacy profile versus traditional treatments in key applications like thyroid ablation, the analyst tells investors in a research note. The firm says Pulse has multiple shots on goal and an experienced CEO.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Pulse Biosciences Inc (PLSE.O) is -13.13, compared to its 5-year average forward P/E of -9.08. For a more detailed relative valuation and DCF analysis to assess Pulse Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.08

Current PE

-13.13

Overvalued PE

-1.81

Undervalued PE

-16.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

118.67

Current PS

430.55

Overvalued PS

346.62

Undervalued PS

-109.28